Skip to content

Effect of Selective iNOS Inhibition During Human Endotoxemia

Effect of Selective iNOS Inhibition During Human Endotoxemia

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00184990
Enrollment
7
Registered
2005-09-16
Start date
2005-01-31
Completion date
2005-09-30
Last updated
2008-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endotoxemia

Keywords

Endotoxemia, Aminoguanidine

Brief summary

Sepsis or endotoxemia is manifested by hypotension, resistance to vasopressors, myocardial depression,and altered organ blood flow distribution. The mechanisms underlying the cardiovascular dysfunction during sepsis are complex; however, they are partially mediated by an uncontrolled production of NO by inducible NO synthase (iNOS).Control subjects received 2 ng/kg E. coli endotoxin, whereas the active intervention group received endotoxin in the presence of selective iNOS-inhibitor aminoguanidine. Hemodynamics, vascular responses to norepinephrine, acetylcholine and sodium nitroprusside, as well as circulating cytokines and other mediators of inflammation were measured. We tested the hypothesis that inhibition of NO-synthesis prevented the LPS-mediated insensitivity to noradrenalin and endothelial-dependent vasorelaxation. Furthermore, we tested whether NO participates in occurrence of the endotoxin tolerance in humans by using the iNOS inhibitor aminoguanidine on healthy volunteers with endotoxemia. At 0; 2 and 4 hours after the LPS challenge whole blood was stimulated with five TLR agonists in vitro and pro- and anti-inflammatory cytokines were measured.

Interventions

DRUGendotoxin

Sponsors

Radboud University Medical Center
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy volunteers

Exclusion criteria

* tendency towards fainting * alcohol abuse * nicotine abuse * drugs abuse

Design outcomes

Primary

MeasureTime frame
Hemodynamics24 hrs after LPS administration
Markers of Inflammation24 hrs after LPS administration
Cytokines24 hrs after LPS administration
Markers of Renal Injury24 hrs after LPS administration
Inducible NO synthase expression24 hrs after LPS administration
NO-metabolites24 hrs after LPS administration
Mediators of Vascular reactivity24 hrs after LPS administration
Sensitivity to norepinephrine24 hrs after LPS administration
Endothelial-dependent vasorelaxation24 hrs after LPS administration

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026